ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment
Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
This study is a placebo-controlled study aimed at assessing the safety of ABX464 administered
at 50 mg and 150 mg o.d. versus placebo in HIV infected patients who are treated with
darunavir + ritonavir (DRV/RTV) or darunavir + cobicistat (DRV/COBI).
Phase:
Phase 2
Details
Lead Sponsor:
Abivax S.A.
Treatments:
Cobicistat Darunavir HIV Protease Inhibitors Protease Inhibitors Ritonavir